Sierra Oncology — Investor Presentation (April 2017)
33 slides from Sierra Oncology's investor presentation, Apr 13, 2017
Slide 1: Beyond PARP - Next Generation DDR Therapeutics
Beyond PARP - Next Generation DDR Therapeutics Q2 2017 Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may c
Slide 3: Sierra Oncology
Sierra Oncology NASDAQ: SRRA Headquarters: Vancouver, BC Development: San Francisco, CA Pro forma Shares (12/31/16): 52.2M* outstanding 58.8M* fully diluted Pro forma Cash on hand (12/31/16): $136.3M* *includes February 2017 financing (~$27.3M; 21.8M shares) net of underwriting discounts, commission
Slide 4: Expanding Beyond PARP
Expanding Beyond PARP The DNA Damage Response (DDR) network is an emerging biological target space for cancer, validated by the clinical success of PARP inhibitors. Lead program SRA737 targets Chk1, a clinically-validated target with potential for synthetic lethality in genetically-defined backgroun
Slide 5: Our Pipeline of 'Next Generation' DDR Therapeutics
Our Pipeline of ‘Next Generation’ DDR Therapeutics Preclinical Phase 1 Phase 2 Targeting Cell division cycle 7 Phase 1 Monotherapy Advanced solid tumors, Currently enrolling Phase 1 Chemotherapy Combination Advanced solid tumors, Currently enrolling Plan to file IND H2 2017 Targeting Checkpoint kina
Slide 6: Beyond PARP: Our DNA Damage Response (DDR) Program
Beyond PARP: Our DNA Damage Response (DDR) Program
Slide 7: DDR Network: Detects DNA Damage, Pauses the Cell Cycle and Repairs DNA
DDR Network: Detects DNA Damage, Pauses the Cell Cycle and Repairs DNA DNA damage detected PARP ATM ATR DDR pathways repair damaged DNA Single strand breaks Double strand breaks Stalled replication forks DDR pathways trigger cell cycle checkpoints S Phase Checkpoint Chk1 Cdc7 Chk1 G1 / S Checkpoint
Slide 8: SRA737 Targeting Chk1
SRA737 Targeting Chk1
Slide 9: Chk1 is an Attractive Emerging Therapeutic Target in Cancer
Cancer Cell Cycle Chk1 is an Attractive Emerging Therapeutic Target in Cancer Defective G1 / S Checkpoint G1/S-defective cancer cells are reliant on remaining Chk1-regulated checkpoints S Phase Checkpoint Chk1 Chk1 G2 / M Checkpoint Chk1 plays an important dual role1) as a key regulator of the cell
Slide 10: SRA737 – Potential Best-In-Class Chk1 Inhibitor
SRA737 – Potential Best-In-Class Chk1 Inhibitor Superior Drug Profile Potent, and superior selectivity for Chk1 vs. Chk2. Excellent oral bioavailability in man enables potential broad clinical utility. Clinically Validated Target Clinical efficacy reported as monotherapy with LY2606368. Gemcitabine
Slide 11: SRA737: Originates from Renowned Drug Discovery Group with Proven Track Record
SRA737: Originates from Renowned Drug Discovery Group with Proven Track Record CRUK/ICR drug discovery track record: Discovered and advanced into the clinic by: Temozolomide for glioblastoma >$1B ww sales* Abiraterone (Zytiga) for advanced prostate cancer >$2B ww sales* *2016 *2008
Slide 12: SRA737: Potentially Superior Chk1 Inhibitor Profile
SRA737: Potentially Superior Chk1 Inhibitor Profile SRA737 selectivity: 15/124 kinases at 10 µM ERK8 = 100x All other kinases >200x CDK2 = 2750x CDK1 = 6750x Cmin Criterion SRA737 LY2606368 GDC-0575 Stage of development: Ph1 Ph2 Ph1 Presentation: Oral i.v. Oral Biochemical IC50: Chk1 1.4 nM ~1 nM 2
Slide 13: Chk1 Inhibition Induces Synthetic Lethality in Genetically-Mutated Cancer Cells
Chk1 Chk1 Inhibition Induces Synthetic Lethality in Genetically-Mutated Cancer Cells Normal Cell Cancer Cell Normal Cell Cancer Cell Cell Survives Cell Survives Cell Survives Cell Death Chk1 Chk1 Normal Inhibited Altered Normal Normal Protein A Protein A Protein A Protein A Altered Normal Chk1 Inhib
Slide 14: Rapid Tumor Regression as Monotherapy in Neuroblastoma Model
7 days consecutive dosing @ 150 mg/kg po MYCN-dependent proliferation of neuronal precursor cells is associated with replication stress. MYCN-transgenic mouse tumors are genetically unstable with chromosomal abnormalities reflective of the human disease. SRA737 treatment results in acute reduction i
Slide 15: Profound Mechanistic Potentiation with DNA-Damaging Gemcitabine
Profound Mechanistic Potentiation with DNA-Damaging Gemcitabine Gemcitabine can induce DNA double strand breaks and stalled replication forks. Preclinical modeling demonstrates extremely robust synergistic anti-tumor activity of SRA737 in combination with gemcitabine. Potential to leverage both pote
Slide 16: Genes Impacting Cell Cycle & DNA Damage Linked to Chk1i Synthetic Lethality
Genes Impacting Cell Cycle & DNA Damage Linked to Chk1i Synthetic Lethality Gene Class Biological Rationale Tumor Suppressors (e.g. TP53, RAD50, etc.) Defective G1/S checkpoint should increase reliance on remaining Chk1-regulated DNA damage checkpoints. Oncogenic Drivers (e.g. MYC, KRAS, etc.) Oncog
Slide 17: Targeting Tumors with Significant Genomic Instability and High Biomarker Prevalence
Targeting Tumors with Significant Genomic Instability and High Biomarker Prevalence Mutational frequencies in oncogenes associated with Chk1i synthetic lethality differ across cancer indications, facilitating rational patient selection strategies. Bladder 11 6 6 11 Ovarian 6 10 10 5 Squamous NSCLC 8
Slide 18: Sierra's Patient Selection Algorithm is Based on Genetic Profiling
Sierra’s Patient Selection Algorithm is Based on Genetic Profiling for Synthetic Lethality “Stack the deck” by requiring mutations in genes that impact both roles of Chk1 -cell cycle and DNA integrity - to maximally enhance potential SRA737 sensitivity. + + + S & G2/M Checkpoint Regulation DDR & Rep
Slide 19: Clinical Validation of Chk1 Monotherapy with Emerging Data for LY2606368
Clinical Validation of Chk1 Monotherapy with Emerging Data for LY2606368 ESMO 2016 Abstract: Phase 2 study in sporadic high-grade serous ovarian cancer and germline BRCA mutation-associated ovarian cancer. AACR 2017 Poster: Phase 1b monotherapy expansion cohort data update in advanced head and neck
Slide 20: Clinical Validation of Chk1/Gemcitabine Combination with Emerging Clinical Data from Genentech
Clinical Validation of Chk1/Gemcitabine Combination with Emerging Clinical Data from Genentech GDC-0425: First generation Chk1 inhibitor 40 patient Phase 1 combination study with gemcitabine. 21 patients had RECIST-evaluable disease and archival tissue for genetic assessment. 2 out of 3 PRs had TP53
Slide 21: Breadth of Development Opportunities Reflected in Sierra's Development Strategy
Breadth of Development Opportunities Reflected in Sierra’s Development Strategy Exploit profound potentiating effects of SRA737 with low dose gemcitabine plus synthetic lethality in genetically-defined populations in two tumor types. Exploit synergy between Chk1 inhibitor + PARP inhibitor to expand/
Slide 22: Monotherapy Phase 1: Innovative Trial Design to Show Synthetic Lethality
Monotherapy Phase 1: Innovative Trial Design to Show Synthetic Lethality Fall 2016: CRUK-sponsored Ph1 monotherapy dose escalation initiated Jan 2017: Sierra assumes sponsorship of SRA737 Sierra Ph1 amendment submission and review Continued dose escalation to MTD Prospective patient selection using
Slide 23: Chemotherapy Combination Phase 1: Leverages Potentiation & Synthetic Lethality
Chemotherapy Combination Phase 1: Leverages Potentiation & Synthetic Lethality Low-dose gem combo dose escalation Bladder Pancreatic Fall 2016: CRUK-sponsored Ph1 monotherapy dose escalation initiated Jan 2017: Sierra assumes sponsorship of SRA737 Sierra Ph1 amendment submission and review Prospecti
Slide 24: SRA737 has Significant Commercial Potential Across Major Market Cancer Indications
SRA737 has Significant Commercial Potential Across Major Market Cancer Indications Monotherapy indications Gemcitabine Combination indications Estimated 20-33% of patients in a given tumor type will be biomarker positive based on our genetic algorithm. [Company Estimates]
Slide 25: SRA737: Upcoming Expected Milestones
SRA737: Upcoming Expected Milestones Medical conference data H2 2018 Preliminary R&D update Early 2018 Medical conference data H2 2018 Preliminary R&D update Early 2018 Q1 17 Q2 17 Q3 17 Q4 17 H1 18 H2 18 Monotherapy PARP Combo I/O Combo Potential Clinical Opportunities Complete formal CTA transfer
Slide 26: SRA141 Targeting Cdc7
SRA141 Targeting Cdc7
Slide 27: SRA141: Selective Small Molecule Targeting Cdc7
SRA141: Selective Small Molecule Targeting Cdc7 SRA141: highly-selective and potent cell division cycle 7 (Cdc7) inhibitor. Cdc7: key regulator of both DNA replication and DNA damage response. Potential development opportunities in solid and liquid tumors. Mono- and combo- therapy development potent
Slide 28: Cdc7: Key Function in DNA Replication
Cdc7: Key Function in DNA Replication Cdc7 activates DNA replication during S-phase in response to growth-promoting signals (e.g. cyclins, Myc, Ras) Cdc7 stabilizes stalled replication forks during replication stress. Cdc7 Chk1 Cyclins Myc Ras Homologous Recombination Repair (HRR) Replication stress
Slide 29: SRA141: Potential First-In-Class/Best-In-Class Opportunity
SRA141: Potential First-In-Class/Best-In-Class Opportunity Preclinical data and published literature suggest a variety of indications with potential for response to Cdc7 inhibitors: Solid tumors: breast, ovarian, pancreatic, melanoma, colorectal, uterine, thyroid, etc. Hematological malignancies: AM
Slide 30: Advancing Targeted Cancer Therapies
Advancing Targeted Cancer Therapies
Slide 31: Proven Leadership in Oncology Development
Proven Leadership in Oncology Development Nick Glover, PhD President and CEO Barbara Klencke, MD Chief Development Officer Angie You, PhD Chief Business & Strategy Officer and Head of Commercial Sukhi Jagpal, CA, CBV, MBA Chief Financial Officer Mark Kowalski, MD, PhD Chief Medical Officer Keith And
Slide 32: Expanding Beyond PARP
Expanding Beyond PARP Cash runway to mid-2019 delivers multiple data readouts, with preliminary data anticipated in early 2018. The DNA Damage Response (DDR) network is an emerging biological target space for cancer, validated by the clinical success of PARP inhibitors. Our pipeline assets are poten
Slide 33: Slide 33